2019
Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer.
Moss HA, Havrilesky LJ, Wang FF, Georgieva MV, Hendrix LH, Dinan MA. Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer. JCO Oncology Practice 2019, 15: e1018-e1027. PMID: 31613721, PMCID: PMC10445789, DOI: 10.1200/jop.19.00026.Peer-Reviewed Original ResearchConceptsAdvanced ovarian cancerOvarian cancerAlternative payment modelsNeoadjuvant chemotherapy patientsEmergency department visitsSEER-Medicare dataMean total costOutpatient emergency department visitsPayment modelsHealth care servicesCost-efficient careAvoidable spendingNeoadjuvant chemotherapyReal-world practiceDepartment visitsChemotherapy patientsCancer careMedicare beneficiariesHospitalizationCare servicesPatientsService MedicareChemotherapySurgeryPotential cost savings
2015
Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.
Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. Journal Of The National Comprehensive Cancer Network 2015, 13: e1-7. PMID: 25583775, DOI: 10.6004/jnccn.2015.0014.Peer-Reviewed Original ResearchConceptsFebrile neutropeniaHigh riskNCCN Clinical Practice GuidelinesBroad-spectrum antibiotic treatmentCommon dose-limiting toxicityChemotherapy dose reductionsConsideration of prophylaxisLow-risk regimensDose-limiting toxicityChemotherapy-induced neutropeniaClinical practice guidelinesHealth care useEpisode of careMyeloid growth factorsGrowth factor useEarly treatment terminationHealth care costsPrimary prophylaxisMyelosuppressive chemotherapySupportive careSerious morbidityTreatment delayTherapeutic optionsAntibiotic treatmentCare use
2014
Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass
Havrilesky LJ, Dinan M, Sfakianos GP, Curtis LH, Barnett JC, Van Gorp T, Myers ER. Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. Journal Of The National Cancer Institute 2014, 107: dju322. PMID: 25515232, DOI: 10.1093/jnci/dju322.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlgorithmsBiomarkers, TumorCA-125 AntigenCost-Benefit AnalysisDecision MakingDisease ManagementFemaleGenital Neoplasms, FemaleHumansMaleMarkov ChainsMedicareMembrane ProteinsMiddle AgedPostmenopausePractice Guidelines as TopicPremenopauseReferral and ConsultationRisk AssessmentSEER ProgramSensitivity and SpecificityUnited StatesWorkloadConceptsPostmenopausal womenAdnexal massesCutoff valueEnd Results-MedicareState Inpatient DatabasesGynecologists guidelinesBiomarker validation studiesPremenopausal womenClinical outcomesGynecologic oncologistsInpatient DatabaseMalignancy AlgorithmSurgical volumeReferral strategiesTriage strategiesMedical costsRelative survivalPhysician workloadCA125Test characteristicsCost-effective strategyWomenTest sensitivityAmerican CongressMedicare reimbursement
2012
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics In Medicine 2012, 15: 203-211. PMID: 22975761, PMCID: PMC3743447, DOI: 10.1038/gim.2012.119.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancerHormonal therapyClinicopathologic characteristicsRisk groupsEarly-stage breast cancerIncremental cost-effectiveness ratioHigh-risk characteristicsLifetime medical costsCost-effectiveness ratioLow-risk characteristicsDecision analytic modelChemotherapy useMedical costsChemotherapyPatientsHealth systemSocietal perspectiveRecurrenceCancerMultifactorial decisionTherapySupportive evidenceTreatment